CD38 and neoplasm: The 68Ga-anti-CD38 nanobody demonstrated rapid accumulation in tumors (1.76 ± 0.305%ID/g (n = 5)) 1 h post-injection, which was accompanied by a promising tumor-to-bone ratio (TBR = 5.79) as well as evidence of rapid renal clearance (Figure 4).